NDAINTRAVENOUSSOLUTION
Approved
Feb 2008
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
COSYNTROPIN (cosyntropin) by Novartis is clinical pharmacology cosyntropin, like acth, binds specific receptors in the plasma membrane of adrenal cortical cells in the zona fasciculata. Approved for infantile spasm, postdural puncture headache. First approved in 2008.
Drug data last refreshed Yesterday
Mechanism of Action
CLINICAL PHARMACOLOGY Cosyntropin, like ACTH, binds specific receptors in the plasma membrane of adrenal cortical cells in the zona fasciculata. The hormone-receptor complex activates adenylate cyclase, which stimulates the production of cyclic AMP. This leads to the conversion of cholesterol to…
Indications (2)
Worked on COSYNTROPIN at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.